NKGN - speculative catalyst play

20 avr. 2024

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

Disclaimer: This is not financial advice.

Key Upcoming Date: 04/25/2024 (Catalyst Event)

Shares Outstanding: 9.02M
Short Interest: 6.89%
Relative Volume as of 04/19/2024: 1.73

This is a very speculative investment opportunity. Due to its nature, a tight stop loss (SL) is recommended:

Stop Loss (SL): Set below $1.00 to manage risk.
Take Profit (TP): Aim for approximately $1.95.

Additional details are provided in the accompanying chart.

Please exercise caution when trading.

23 avr. 2024

Trade fermée: cible de profit atteinte

we might going way higher.